HHS IG Compliance Guide For Rx Industry Planned For Year-End
The HHS Inspector General plans to publish a compliance program guidance for the pharmaceutical industry around the end of the year.
You may also be interested in...
The pharmaceutical industry should pay greater attention to the costs associated with corporate integrity agreements included in False Claims Act liability settlements, attorney Lynn Snyder (Epstein Becker & Green) suggested.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011